RDL6 Antibody
Description
Clarification of Terminology
The term "RDL6" does not correspond to any validated protein, receptor, or antigen in major biomedical databases (e.g., UniProt, NCBI Gene). Potential sources of confusion include:
-
RDL (Resistance to Dieldrin): A GABA<sub>A</sub> receptor subunit in insects, studied in honeybee neurobiology . Antibodies targeting RDL have been developed for research in insect models but are unrelated to "RDL6" .
-
LRP6 (Low-Density Lipoprotein Receptor-Related Protein 6): A Wnt signaling coreceptor with therapeutic antibodies under investigation for cancer and metabolic diseases . This is distinct from "RDL6."
Anti-RDL Antibodies
| Target | Application | Species | Key Findings |
|---|---|---|---|
| RDL (GABA receptor) | Neuroscience research in Apis mellifera | Honeybee | CRISPR-Cas9 validated antibodies localize RDL in bee brain sections . |
Anti-LRP6 Antibodies
Potential Explanations for Absence of Data
-
Typographical Error: "RDL6" may be a misspelling of RDL (insect GABA receptor) or LRP6 (Wnt coreceptor).
-
Obscure or Emerging Target: If "RDL6" refers to a novel or uncharacterized antigen, no peer-reviewed studies are currently available.
-
Proprietary or Unpublished Data: The term might relate to internal project names in undisclosed industry research.
Recommendations for Further Inquiry
-
Verify the intended target (e.g., RDL, LRP6, or other receptors).
-
Explore databases like ClinicalTrials.gov or antibody registries (e.g., Antibody Society) for emerging candidates.
-
Consult structural databases (e.g., PDB) for protein homologs or paralogs.
Product Specs
Target Background
Q&A
How to validate RDL6 antibody specificity for Western blot applications in novel cell lines?
Methodological approach:
-
Perform knockout/knockdown controls using CRISPR or siRNA targeting the RDL6 gene. Compare protein expression between wild-type and modified cell lysates .
-
Use secondary antibody-only controls to rule out nonspecific binding.
-
Validate with independent antibodies targeting distinct RDL6 epitopes for cross-verification .
Key validation metrics:
| Parameter | Ideal Outcome | Common Pitfalls |
|---|---|---|
| Band specificity | Single band at expected molecular weight | Multiple bands (proteolysis/degradation) |
| Signal-to-noise ratio | ≥5:1 in target samples | High background in controls |
What experimental parameters influence RDL6 antibody performance in immunohistochemistry (IHC)?
Critical factors:
-
Fixation time: Overfixation (>24 hr in formalin) masks epitopes, while underfixation (<6 hr) causes poor morphology .
-
Antigen retrieval: Optimize pH (6.0 vs. 9.0) and heat-mediated methods (pressure cooker vs. microwave).
-
Blocking buffers: Compare protein-based (BSA) vs. serum-based blockers for tissue-specific background reduction.
Advanced troubleshooting:
-
Use multiplex fluorescence IHC with spectral unmixing to confirm colocalization patterns.
-
Quantify staining intensity using H-score systems to avoid subjective interpretation .
How to resolve contradictory RDL6 expression data between ELISA and flow cytometry?
Root-cause analysis framework:
-
Epitope accessibility: Confirm whether the antibody recognizes linear (denatured) vs. conformational epitopes.
-
Sample preparation: Compare lysate buffers (RIPA vs. NP-40) for ELISA and cell viability dyes for flow cytometry.
-
Cross-reactivity screening: Use recombinant protein arrays to identify off-target interactions .
Standardization checklist:
-
Report batch-specific validation data (≥3 biological replicates)
-
Document precise dilution factors (e.g., 1:500 ± 10%) rather than qualitative descriptions
Collaborative validation:
| Parameter | Inter-lab Protocol |
|---|---|
| Cell lysate quantity | 20μg/lane ± 2μg (BCA-validated) |
| Incubation time | 1hr RT ± 5min (temperature-controlled) |
How to design RDL6 knockdown experiments accounting for antibody cross-reactivity?
Advanced experimental design:
-
Multi-target validation:
-
Use CRISPRi/a systems with dose-dependent repression/activation
-
Combine with proteomics profiling to detect off-target effects
-
-
Time-course analysis:
-
Monitor protein turnover rates (pulse-chase) vs. antibody detection limits
-
Integrated validation pipeline:
-
Structural prediction: Use AlphaFold2 models to map antibody-epitope interactions
-
Transcriptome correlation: Compare protein/mRNA levels across 10+ cell types
-
Public data mining: Curate expression patterns from >5 independent studies
Validation scorecard:
| Tool | Application | Validation Weight |
|---|---|---|
| CPTAC Assay Portal | Mass-spec cross-validation | 35% |
| Human Protein Atlas | Tissue-specific expression patterns | 25% |
| COSMIC Database | Mutation-associated expression shifts | 40% |
